Effect of dapagliflozin combined with pioglitazone in the treatment of type 2 diabetes mellitus and its influences on FABP4 and PPARγ
Objective To analyze the effect of dapagliflozin combined with pioglitazone in the treatment of type 2 diabetes mellitus(T2DM)and its influences on fatty acid binding protein 4(FABP4)and peroxisome proliferator-activated receptor γ(PPARy).Methods A total of 90 patients with T2DM admitted from May 2020 to May 2022 were selected as the research objects and divided into control group and observation group according to the random number table method,with 45 cases in each group.The control group was treated with pioglitazone,and the observation group was treated with dapagliflozin on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was significantly higher than that in the control group(P＜0.05).After treatment,the level of FABP4 in the observation group was lower than that in the control group,and the level of PPARγ was higher than that in the control group(P＜0.05).After treatment,the homeostasis model assessment of islet βcell secretory function index(HOMA-β)and insulin sensitivity index(ISI)in the observation group were higher than those in the control group,and the homeostasis model assessment-insulin resistance(HOMA-IR)was lower than that of the control group(P＜0.05).After treatment,the glycosylated hemoglobin(HbA1c),visceral fat area and triglyceride(TG)level in the observation group were lower than those in the control group(P＜0.05).Conclusion Dapagliflozin combined with pioglitazone in the treatment of T2DM can not only improve the therapeutic effect,but also regulate the levels of FABP4 and PPARγ,improve insulin resistance(IR),and down-regulate the blood glucose and blood lipid levels of patients,which is worthy of further clinical promotion and application.
NETL
NSTL
万方数据
